Circulation-Heart Failure:美国成年心衰患者的血压和血糖控制情况

2022-05-07 MedSci原创 MedSci原创

在这个具有全国代表性的心衰患病样本中,研究人员报道了不受控制高血压和糖化血红蛋白的患病率,并在不同种族和民族的患者中血压控制存在显著差异。

多项指南建议,无论射血分数如何,心力衰竭(HF)患者的目标收缩压(BP)<130mmhg,目标糖化血红蛋白(HbA1c)<8%。很少有研究描述门诊心衰患者的血压和血糖控制水平,以及这部分人群的种族和民族差异。

近日,心血管领域权威杂志Circulation: Heart Failure上发表了一篇研究文章,研究人员评估了年龄≥20岁的自我报告心衰的非西班牙裔黑人、非西班牙裔白人和墨西哥裔美国人血压和糖化血红蛋白未受到有效控制的患病率(2001-2018年全国健康和营养检查调查)。

此外,研究人员根据种族和民族计算了受试者未控制的血压和糖化血红蛋白的患病率(95%CI),并根据性别、年龄、治疗和社会经济地位进行调整。在二次分析中,研究人员评估了未控制的血压和糖化血红蛋白的患病趋势。

48%(95%CI为49%-56%)的心衰患者(约230万人)存在血压未受控制。非西班牙裔黑人受试者与非西班牙裔白人受试者相比,血压未受控制的患病率更高(53%[48%-58%] vs. 47%[43%-51%],P<0.05)。在调整后的模型中,非西班牙裔黑人参与者患血压未受控制的可能性是非西班牙裔白人参与者的1.19倍(1.02-1.39)。总体而言,未受控制的糖化血红蛋白占8%(6%-10%),种族和民族无差异。未受控制血压的患病率随着时间的推移有所改善,但未受控制的危险因素仍然很高—2017年至2018年分别有41%(36%-47%)的受试者血压和7%(5%-12%)的受试者糖化血红蛋白未受控制。

由此可见,在这个具有全国代表性的心衰患病样本中,研究人员报道了不受控制高血压和糖化血红蛋白的患病率,并在不同种族和民族的患者中血压控制存在显著差异。

原始出处:

Leah Rethy, et al.Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circulation: Heart Failure. 2022; https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.121.009229

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906215, encodeId=124519062154e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Jan 04 18:53:03 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273072, encodeId=725212e3072ce, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357911, encodeId=ea6c135e911e6, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373566, encodeId=59ac13e3566e3, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563605, encodeId=3142156360543, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=)]
    2023-01-04 amy0550
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906215, encodeId=124519062154e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Jan 04 18:53:03 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273072, encodeId=725212e3072ce, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357911, encodeId=ea6c135e911e6, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373566, encodeId=59ac13e3566e3, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563605, encodeId=3142156360543, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906215, encodeId=124519062154e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Jan 04 18:53:03 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273072, encodeId=725212e3072ce, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357911, encodeId=ea6c135e911e6, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373566, encodeId=59ac13e3566e3, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563605, encodeId=3142156360543, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=)]
    2022-05-09 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906215, encodeId=124519062154e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Jan 04 18:53:03 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273072, encodeId=725212e3072ce, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357911, encodeId=ea6c135e911e6, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373566, encodeId=59ac13e3566e3, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563605, encodeId=3142156360543, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906215, encodeId=124519062154e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Jan 04 18:53:03 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273072, encodeId=725212e3072ce, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357911, encodeId=ea6c135e911e6, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373566, encodeId=59ac13e3566e3, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563605, encodeId=3142156360543, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon May 09 02:53:03 CST 2022, time=2022-05-09, status=1, ipAttribution=)]
    2022-05-09 slcumt

相关资讯

JAHA:肥胖、凝集素-3与心衰的关系

肥胖与凝集素-3水平升高密切相关。此外,肥胖和高凝血素-3水平相结合与显著的心衰风险相关,这强调了阐明肥胖与心脏炎症和纤维化相关途径的重要性。

ACC/AHA/HFSA 2022:推荐SGLT-2抑制剂用于治疗心衰

无论糖尿病状况如何,DAPA-HF 和 EMPEROR-HF 试验都证明用 SGLT-2 抑制剂治疗 HFrEF 患者的益处,显示心力衰竭再住院率降低了 30%。

Ann Intern Med:心衰患者钠-葡萄糖共转运蛋白2抑制剂的效果分析

随机对照试验确定了钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂对2型糖尿病患者具有心脏保护作用。新的证据表明,这些结果可以扩展到没有糖尿病的个体。